Type 2 diabetes THE ONLY
SGLT2i indicated to reduce the risk of CV death * 1 , 2
Heart failure THE FIRST
SGLT2i indicated across the LVEF spectrum † ^1
Chronic kidney disease THE BROADEST indication of any SGLT2i for CKD ‡ 1 , 2
JARDIANCE ® has a consistent and established safety profile across indications . Very common adverse reactions : hypoglycaemia ( combination with metformin and an SU ; insulin - patients with T2D ); volume depletion ( patients with HF ). Common : hypoglycaemia ( combination with metformin ; pioglitazone with or without metformin ; metformin and linagliptin- patients with T2D ); hypoglycaemia ( T2D patients with HF ); UTIs ; increased urination ; vaginal moniliasis , vulvovaginitis , balanitis and other genital infections ; volume depletion ( T2D patients aged ≥75 years ); thirst ( patients with T2D ); pruritis ( patients with T2D ); serum lipids increased ; constipation . Precautions include patients with type 1 diabetes ; ketoacidosis ; surgery . Please refer to the full JARDIANCE ® Approved Product Information for information on other Precautions and Adverse Reactions .
References : 1 . JARDIANCE ® Product Information . 2 . Therapeutic Goods Administration . Available at : https :// www . tga . gov . au . Accessed February 2025 .
Abbreviations : CAD , coronary artery disease ; CKD , chronic kidney disease ; CV , cardiovascular ; eCVD , established cardiovascular disease ; HF , heart failure ; LVEF , left ventricular ejection fraction ; MI , myocardial infarction ; PAD , peripheral artery disease ; SGLT2i , sodium-glucose cotransporter 2 inhibitor ; SOC , standard of care ; T2D , type 2 diabetes ; TGA , Therapeutic Goods Administration ; uACR , urine albumin to creatinine ratio ; UTI , urinary tract infection .
Boehringer Ingelheim Pty Limited , ABN 52 000 452 308 . 78 Waterloo Road , North Ryde , NSW 2113 Australia . Copyright © 2025 . PC-AU-104258 . Prepared February 2025 . BOEH0911 _ AusDoc .